Kalaris Therapeutics
KLRS
58 hedge funds and large institutions have $107M invested in Kalaris Therapeutics in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 7 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 7
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
14% more funds holding
Funds holding: 51 → 58 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15.19% less ownership
Funds ownership: 96.22% → 81.03% (-15%)
29% less capital invested
Capital invested by funds: $152M → $107M (-$44.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$2.25M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.5M |
| 3 |
Goldman Sachs
New York
|
+$676K |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$598K |
| 5 |
Millennium Management
New York
|
+$528K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$700K |
| 2 |
6CM
683 Capital Management
New York
|
-$316K |
| 3 |
Jane Street
New York
|
-$279K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$253K |
| 5 |
Renaissance Technologies
New York
|
-$192K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$89 | -10 | -9% |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $802 | +$1.23K | +139 | New |
|
|
FFO
53
Fortitude Family Office
Scottsdale,
Arizona
| $658 | – | – | – |
|
|
PA
54
Parallel Advisors
San Francisco,
California
| $283 | – | – | – |
|
55
JP Morgan Chase
New York
| $265 | – | – | – |
|
56
Federated Hermes
Pittsburgh,
Pennsylvania
| $196 | +$302 | +34 | New |
|
|
HI
57
Harbour Investments
Madison,
Wisconsin
| $75 | +$115 | +13 | New |
|
|
SS
58
SBI Securities
Tokyo,
Japan
| $29 | – | – | – |
|
|
RG
59
Redmile Group
San Francisco,
California
| – | -$700K | -82,955 | Closed |
|
|
60
Jane Street
New York
| – | -$279K | -33,114 | Closed |
|
|
OAC
61
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$253K | -30,000 | Closed |
|
62
Walleye Capital
New York
| – | -$94.7K | -11,225 | Closed |
|
|
XT
63
XTX Topco
George Town,
Cayman Islands
| – | -$92K | -10,897 | Closed |
|
|
KP
64
Keel Point
Huntsville,
Alabama
| – | -$86.3K | -10,225 | Closed |
|
65
Bank of America
Charlotte,
North Carolina
| – | -$56.6K | -6,704 | Closed |
|
KLRS Hedge Fund Activity: Q1 2026 in Review
58 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2026, worth a combined $107M — down 29% from $152M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KLRS positions and 7 closed out — a net gain of 8 holders — while 16 added to existing stakes and 7 trimmed.
The largest buyer was Propel Bio Management, adding an estimated $2.25M. The largest seller was Redmile Group, exiting entirely with an estimated $700K sold.
- 58 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2026, up from 51 in Q4 2025.
- Funds reported $107M of Kalaris Therapeutics stock for Q1 2026, down 29% quarter-over-quarter.
- 15 funds opened new Kalaris Therapeutics positions in Q1 2026 and 7 closed out, a net change of +8 holders.
- The largest Kalaris Therapeutics buyer in Q1 2026 was Propel Bio Management, an estimated $2.25M added.
- The largest Kalaris Therapeutics seller in Q1 2026 was Redmile Group, an estimated $700K sold.
Based on aggregated 13F filings for Q1 2026.